Phospho-Rb(S788) Antibody
Affinity Purified Rabbit Polyclonal Antibody (Pab)
- SPECIFICATION
- CITATIONS: 1
- PROTOCOLS
- BACKGROUND
Application
| IHC-P, DB, E |
---|---|
Primary Accession | P06400 |
Reactivity | Human |
Host | Rabbit |
Clonality | Polyclonal |
Isotype | Rabbit IgG |
Calculated MW | 106159 Da |
Gene ID | 5925 |
---|---|
Other Names | Retinoblastoma-associated protein, p105-Rb, pRb, Rb, pp110, RB1 |
Target/Specificity | This Rb Antibody is generated from rabbits immunized with a KLH conjugated synthetic phosphopeptide corresponding to amino acid residues surrounding S788 of human Rb. |
Dilution | IHC-P~~1:50~100 DB~~1:500 |
Format | Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification. |
Storage | Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles. |
Precautions | Phospho-Rb(S788) Antibody is for research use only and not for use in diagnostic or therapeutic procedures. |
Name | RB1 |
---|---|
Function | Tumor suppressor that is a key regulator of the G1/S transition of the cell cycle (PubMed:10499802). The hypophosphorylated form binds transcription regulators of the E2F family, preventing transcription of E2F-responsive genes (PubMed:10499802). Both physically blocks E2Fs transactivating domain and recruits chromatin- modifying enzymes that actively repress transcription (PubMed:10499802). Cyclin and CDK-dependent phosphorylation of RB1 induces its dissociation from E2Fs, thereby activating transcription of E2F responsive genes and triggering entry into S phase (PubMed:10499802). RB1 also promotes the G0-G1 transition upon phosphorylation and activation by CDK3/cyclin-C (PubMed:15084261). Directly involved in heterochromatin formation by maintaining overall chromatin structure and, in particular, that of constitutive heterochromatin by stabilizing histone methylation. Recruits and targets histone methyltransferases SUV39H1, KMT5B and KMT5C, leading to epigenetic transcriptional repression. Controls histone H4 'Lys-20' trimethylation. Inhibits the intrinsic kinase activity of TAF1. Mediates transcriptional repression by SMARCA4/BRG1 by recruiting a histone deacetylase (HDAC) complex to the c-FOS promoter. In resting neurons, transcription of the c-FOS promoter is inhibited by BRG1- dependent recruitment of a phospho-RB1-HDAC1 repressor complex. Upon calcium influx, RB1 is dephosphorylated by calcineurin, which leads to release of the repressor complex (By similarity). |
Cellular Location | Nucleus. Cytoplasm {ECO:0000250|UniProtKB:P13405}. Note=During keratinocyte differentiation, acetylation by KAT2B/PCAF is required for nuclear localization (PubMed:20940255). Localizes to the cytoplasm when hyperphosphorylated (By similarity). {ECO:0000250|UniProtKB:P13405, ECO:0000269|PubMed:20940255} |
Tissue Location | Expressed in the retina. Expressed in foreskin keratinocytes (at protein level) (PubMed:20940255) |
Provided below are standard protocols that you may find useful for product applications.
Background
RB1 likely acts as a regulator of other genes. It forms a complex with adenovirus E1A and with SV40 large T antigen, acts as a tumor suppressor, and may bind and modulate functionally certain cellular proteins with which T and E1A compete for pocket binding. RB1 is a potent inhibitor of E2F-mediated trans-activation, and also recruits and targets histone methyltransferase SUV39H1 leading to epigenetic transcriptional repression. This protein inhibits the intrinsic kinase activity of TAF1. Defects in RB1 are the cause of childhood cancer retinoblastoma (RB), a congenital malignant tumor that arises from the nuclear layers of the retina. Defects in RB1 are also a cause of bladder cancer and osteogenic sarcoma.
References
Wagner, S., et al., Biochem. Pharmacol. 69(7):1059-1067 (2005).
Roesch, A., et al., Mod. Pathol. 18(4):565-572 (2005).
Lieman, J.H., et al., J. Biol. Chem. 280(11):10484-10490 (2005).
Budde, A., et al., Oncogene 24(10):1802-1808 (2005).
Zapata, E., et al., FEBS J. 272(6):1343-1353 (2005).
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.